U.S. Court of Appeals for the Federal Circuit, 2026

Janssen Pharmaceuticals, Inc. v. Tolmar, Inc.

Janssen Pharmaceuticals, Inc. v. Tolmar, Inc.
U.S. Court of Appeals for the Federal Circuit · Decided May 5, 2026
Janssen Pharmaceuticals, Inc. v. Tolmar, Inc.

Opinion

Case: 24-1699 Document: 36 Page: 1 Filed: 05/05/2026

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit

______________________

JANSSEN PHARMACEUTICALS, INC., JANSSEN

PHARMACEUTICA NV, Plaintiffs-Cross-Appellants v. TOLMAR, INC., Defendant-Appellant ______________________

2024-1699, 2024-1700, 2024-1980, 2024-2020

______________________

Appeals from the United States District Court for the District of Delaware in No. 1:21-cv-01784-WCB-SRF, Cir- cuit Judge William C. Bryson.

______________________ ON MOTION ______________________

Before LOURIE, TARANTO, and CHEN, Circuit Judges. PER CURIAM.

ORDER

Having “agreed to resolve all claims between them” in this matter, ECF No. 34 at 7, the parties jointly move to remand these appeals in light of the district court’s April 3, 2026 indicative ruling that it would vacate its March 13, Case: 24-1699 Document: 36 Page: 2 Filed: 05/05/2026 2 JANSSEN PHARMACEUTICALS, INC. v. TOLMAR, INC. 2024 final judgment and enter a consent judgment if this court remanded.

This court takes no position on the propriety or neces- sity of any vacatur, leaving it to the district court to con- sider the principles enunciated in United States Bancorp Mortgage Co. v. Bonner Mall Partnership, 513 U.S. 18, 29 (1994).

Accordingly, IT IS ORDERED THAT: (1) The motion is granted to the extent that the ap- peals are remanded.

(2) Each side shall bear its own costs.

FOR THE COURT May 5, 2026

Date ISSUED AS A MANDATE: May 5, 2026

Case-law data current through September 30, 2026. Source: CourtListener bulk data.